Takayama K - Search Results

1

Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis.

Kanbayashi Y, Sakaguchi K, Ishikawa T, Takayama K, Taguchi T. Kanbayashi Y, et al. Among authors: takayama k. Sci Rep. 2021 Oct 8;11(1):20055. doi: 10.1038/s41598-021-99504-5. Sci Rep. 2021. PMID: 34625634 Free PMC article.

2

Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer.

Watanabe H, Ikesue H, Oshiro M, Nagata K, Mishima K, Takada A, Suetsugu K, Sueyasu M, Egashira N, Harada T, Takayama K, Nakanishi Y, Oishi R. Watanabe H, et al. Among authors: takayama k. Chemotherapy. 2012;58(6):419-25. doi: 10.1159/000345617. Epub 2013 Jan 4. Chemotherapy. 2012. PMID: 23295219 Free article.

3

Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer.

Ikesue H, Watanabe H, Hirano M, Chikamori A, Suetsugu K, Ryokai Y, Egashira N, Yamada T, Ikeda M, Iwama E, Harada T, Takayama K, Nakanishi Y, Masuda S. Ikesue H, et al. Among authors: takayama k. Biol Pharm Bull. 2015;38(8):1192-8. doi: 10.1248/bpb.b15-00162. Biol Pharm Bull. 2015. PMID: 26235582 Free article.

4

Predictive factors in patients eligible for pegfilgrastim prophylaxis focusing on RDI using ordered logistic regression analysis.

Kanbayashi Y, Ishikawa T, Kanazawa M, Nakajima Y, Kawano R, Tabuchi Y, Yoshioka T, Ihara N, Hosokawa T, Takayama K, Shikata K, Taguchi T. Kanbayashi Y, et al. Among authors: takayama k. Med Oncol. 2018 Mar 16;35(4):55. doi: 10.1007/s12032-018-1116-5. Med Oncol. 2018. PMID: 29549536

5

Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.

Kanbayashi Y, Ishikawa T, Kanazawa M, Nakajima Y, Tabuchi Y, Kawano R, Yoshioka T, Yoshida N, Hosokawa T, Takayama K, Taguchi T. Kanbayashi Y, et al. Among authors: takayama k. Med Oncol. 2018 Apr 28;35(6):82. doi: 10.1007/s12032-018-1142-3. Med Oncol. 2018. PMID: 29705823

6

Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis.

Kanbayashi Y, Sakaguchi K, Nakatsukasa K, Ouchi Y, Tabuchi Y, Yoshioka T, Ishikawa T, Takayama K, Taguchi T. Kanbayashi Y, et al. Among authors: takayama k. Support Care Cancer. 2019 Jul;27(7):2673-2677. doi: 10.1007/s00520-018-4571-9. Epub 2018 Nov 26. Support Care Cancer. 2019. PMID: 30478672

7

Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens.

Yoshida N, Taguchi T, Nakanishi M, Inoue K, Okayama T, Ishikawa T, Otsuji E, Takayama K, Kuroboshi H, Kanazawa M, Itoh Y. Yoshida N, et al. Among authors: takayama k. BMC Pharmacol Toxicol. 2019 Jan 14;20(1):6. doi: 10.1186/s40360-018-0278-2. BMC Pharmacol Toxicol. 2019. PMID: 30642399 Free PMC article.

8

Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade.

Sakakida T, Ishikawa T, Uchino J, Chihara Y, Komori S, Asai J, Narukawa T, Arai A, Kobayashi T, Tsunezuka H, Kosuga T, Konishi H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Sakakida T, et al. Among authors: takayama k. Oncol Lett. 2019 Aug;18(2):2140-2147. doi: 10.3892/ol.2019.10466. Epub 2019 Jun 12. Oncol Lett. 2019. PMID: 31423288 Free PMC article.

9

Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.

Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, Komori S, Asai J, Narukawa T, Arai A, Tsunezuka H, Kosuga T, Konishi H, Moriguchi M, Yasuda H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Sakakida T, et al. Among authors: takayama k. Clin Transl Oncol. 2020 Jun;22(6):919-927. doi: 10.1007/s12094-019-02214-8. Epub 2019 Oct 1. Clin Transl Oncol. 2020. PMID: 31576495

10

Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis.

Kanbayashi Y, Ishikawa T, Tabuchi Y, Sakaguchi K, Ouchi Y, Otsuji E, Takayama K, Taguchi T. Kanbayashi Y, et al. Among authors: takayama k. Sci Rep. 2020 Feb 6;10(1):2011. doi: 10.1038/s41598-020-58994-5. Sci Rep. 2020. PMID: 32029849 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,164 results

Search Page